May 14, 2019 / 06:20PM GMT
Tazeen Ahmad - BofA Merrill Lynch, Research Division - VP
Thank you for joining us at the Bank of America Merrill Lynch Conference. I'm Tazeen Ahmad. I'm the senior SMID biotech analyst. It's my pleasure to introduce the next company, DBV Technologies. Sitting next to me are 2 members from the management team, CEO, Daniel Tassé; and Chief Commercial Officer, Kevin Trapp. This will be a Q&A session, so please feel free to ask any questions you have.
But maybe, Daniel, as an introduction for those who may not know the company as well, maybe you can talk to us for a couple of minutes about DBV, its platform and kind of where you're at right now.
Daniel Tassé,DBV Technologies S.A.-CEO&Director
Absolutely. I can bellow or use your mic. Thank you. Good morning, all. My name is Daniel Tassé. I'm the CEO of DBV Technologies. We are a company that is looking at exploiting the extraordinary potential of epicutaneous tissues, essentially the skin, as an immune organ. The skin has incredible potential to simulate
DBV Technologies SA at Bank of America Merrill Lynch Health Care Conference Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot